Symptom Experience of Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Following High Dose Chemotherapy
- Conditions
- C90Multiple myeloma and malignant plasma cell neoplasms
- Registration Number
- DRKS00004345
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
All Patients with MM, and 18 years of age and older admitted to one of the three transplant wards of the Department of Hematology/Oncology, University Medical Center, Freiburg, Germany, for HD and ASCT will be screened for inclusion criteria and consecutively included in the study. The criteria for inclusion are that the patients are able to read, understand, and answer the PROVIVO questionnaire and that HD and ASCT is part of the first treatment regimen after diagnosis.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptom experience of patients will be measured with the PROVIVO questionnaire at four timepoints: admission (day -4, calculated from day of ASCT), nadir (moment of lowest count of white blood cells, about day +7 to +10), discharge (about day +15) and one month after discharge of HD and ASCT (30 days after discharge).
- Secondary Outcome Measures
Name Time Method Evaluation of the PROVIVO questionnaire for the use with patients with multiple myeloma and HD and ASCT